LYEL - Lyell Immunopharma, Inc.
IEX Last Trade
0.6608
0.008 1.165%
Share volume: 9,589
Last Updated: Fri 27 Dec 2024 05:30:42 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
-0.39%
PREVIOUS CLOSE
CHG
CHG%
$0.65
0.01
1.18%
Fundamental analysis
12%
Profitability
0%
Dept financing
3%
Liquidity
75%
Performance
11%
Performance
5 Days
-0.44%
1 Month
-33.65%
3 Months
-59.68%
6 Months
-52.85%
1 Year
-71.23%
2 Year
-79.90%
Key data
Stock price
$0.66
DAY RANGE
$0.65 - $0.70
52 WEEK RANGE
$0.63 - $3.26
52 WEEK CHANGE
-$70.95
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/05/2024
Company detail
CEO: Elizabeth Homans
Region: US
Website: lyell.com
Employees: 270
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: lyell.com
Employees: 270
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Lyell Immunopharma, Inc. engages in developing T cell therapies for patients with solid tumors. Its pipeline includes LYL797, a T cell product candidate for the treatment of non-small cell lung cancer and triple negative breast cancers. The company entered into research and development collaboration with GlaxoSmithKline for NY-ESO-1 program.
Recent news